Search
Nizofenone
go.drugbank.com/drugs/DB13546ExperimentalCategories: Compounds used in a research, industrial, or household settingAcriflavine
go.drugbank.com/drugs/DB13373InvestigationalCategories: Compounds used in a research, industrial, or household settingNV-18
go.drugbank.com/drugs/DB05886ExperimentalLike phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer.
Silmitasertib
go.drugbank.com/drugs/DB15408InvestigationalSilmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
Categories: Casein Kinase II, antagonists & inhibitorsZunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.
H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalH3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551].
Synonyms: (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(2-pyridinyl)-2,4-heptadien-2-yl]oxacyclododec-4-en-6-yl 4-methyl-1-piperazinecarboxylate, (2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-Dimethyl-12-Oxo-2-[(2E,4E,6R)-6-(Pyridin-2-Yl)Hepta-2,4-Dien-2-Yl]Oxacyclododec-4-En-6-Yl 4-Methylpiperazine-1-CarboxylateXL765
go.drugbank.com/drugs/DB05241InvestigationalXL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). … It is being developed by Exelixis, Inc.
Human Menstrual Blood-derived Stem Cells
go.drugbank.com/drugs/DB15738InvestigationalBecause this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind. … MenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method.
Butyrfentanyl
go.drugbank.com/drugs/DB09173ExperimentalIllicit[L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl. … [A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.